Innate immune activation and cystic fibrosis

Paediatric Respiratory Reviews

Volumn 9, Issue 4, 2008, Pages 271-280

  Brennan, Siobhain ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

cystic fibrosis; innate defence; macrophage; neutrophil; oxidative stress

Indexed keywords

ALPHA DEFENSIN; ANTIOXIDANT; BETA DEFENSIN; CD14 ANTIGEN; GLUTATHIONE; LEUKOCYTE ELASTASE; MATRIX METALLOPROTEINASE; REACTIVE OXYGEN METABOLITE; SURFACTANT PROTEIN A; SURFACTANT PROTEIN D; TOLL LIKE RECEPTOR; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ANTIOXIDANT ACTIVITY; BACTERIAL COLONIZATION; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; CHRONIC INFLAMMATION; CYSTIC FIBROSIS; EPITHELIUM CELL; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMORAL IMMUNITY; INFECTION SENSITIVITY; INFLAMMATORY CELL; INNATE IMMUNITY; LEUKOCYTE ACTIVATION; LUNG ALVEOLUS MACROPHAGE; MOLECULAR RECOGNITION; MUCOCILIARY CLEARANCE; NEUTROPHIL; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RESPIRATORY EPITHELIUM; REVIEW;

CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; EPITHELIAL CELLS; HUMANS; IMMUNITY, INNATE; MACROPHAGES; NEUTROPHILS; OXIDATIVE STRESS;

EID: 56049091722     PISSN: 15260542     EISSN: 15260550     Source Type: Journal    
DOI: 10.1016/j.prrv.2008.05.008     Document Type: Review

References (100)

1. Armstrong D., Grimwood K., Carzino R., Carlin J., Olinsky A., and Phelan P. Lower respiratory infection and inflammation in infants with newly diagnosed cystic fibrosis. BMJ 310 (1995) 1571-1572
2. Balough K., McCubbin M., Weinberger M., Smits W., Ahrens R., and Fick R. The relationship between infection and inflammation in the early stages of lung disease from cystic fibrosis. Paediatr Pulmonol 20 (1995) 63-70
3. Brennan S., Hall G.L., Horak F., et al. Correlation of forced oscillation technique in preschool children with cystic fibrosis with pulmonary inflammation. Thorax 60 (2005) 159-163
4. Khan T.Z., Wagener J.S., Bost T., Martinez J., Accurso F.J., and Riches D. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 151 (1995) 1075-1082
5. Saiman L. Microbiology of early CF lung disease. Paediatr Respir Rev 5 Suppl. A (2004) S367-369
6. Hubeau C., Puchelle E., and Gaillard D. Distict patterns of immune cell populations in the lung of human fetuses with cystic fibrosis. J Allergy Clin Immunol 108 (2001) 524-529
7. Rubin B.K. Mucus structure and properties in cystic fibrosis. Paediatr Respir Rev 8 (2007) 4-7
8. Elkins M.R., and Bye P.T. Inhaled hypertonic saline as a therapy for cystic fibrosis. Curr Opin Pulm Med 12 (2006) 445-452
9. Chilvers M.A., and O'Callaghan C. Local mucociliary defence mechanisms. Paediatr Respir Rev 1 (2000) 27-34
10. Hartl D., and Griese M. Surfactant protein D in human lung diseases. Eur J Clin Invest 36 (2006) 423-435
11. Meyer K.C., and Zimmerman J.J. Inflammation and surfactant. Paediatr Respir Rev 3 (2002) 308-314
12. Schneider J.J., Unholzer A., Schaller M., Schafer-Korting M., and Korting H.C. Human defensins. J Mol Med 83 (2005) 587-595
13. van Wetering S., Sterk P.J., Rabe K.F., and Hiemstra P.S. Defensins: key players or bystanders in infection, injury, and repair in the lung?. J Allergy Clin Immunol 104 (1999) 1131-1138
14. Porro G.A., Lee J.H., de Azavedo J., et al. Direct and indirect bacterial killing functions of neutrophil defensins in lung explants. Am J Physiol Lung Cell Mol Physiol 281 (2001) L1240-1247
15. Goldman M.J., Anderson G.M., Stolzenberg E.D., Kari U.P., Zasloff M., and Wilson J.M. Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell 88 (1997) 553-560
16. Bals R., Weiner D.J., Meegalla R.L., Accurso F., and Wilson J.M. Salt-independent abnormality of antimicrobial activity in cystic fibrosis airway surface fluid. Am J Respir Cell Mol Biol 25 (2001) 21-25
17. Chen C.I., Schaller-Bals S., Paul K.P., Wahn U., and Bals R. Beta-defensins and LL-37 in bronchoalveolar lavage fluid of patients with cystic fibrosis. J Cyst Fibros 3 (2004) 45-50
18. Dauletbaev N., Gropp R., Frye M., Loitsch S., Wagner T.O., and Bargon J. Expression of human beta defensin (HBD-1 and HBD-2) mRNA in nasal epithelia of adult cystic fibrosis patients, healthy individuals, and individuals with acute cold. Respiration 69 (2002) 46-51
19. Claeys S., Van Hoecke H., Holtappels G., et al. Nasal polyps in patients with and without cystic fibrosis: a differentiation by innate markers and inflammatory mediators. Clin Exp Allergy 35 (2005) 467-472
20. Taggart C.C., Greene C.M., Smith S.G., et al. Inactivation of human beta-defensins 2 and 3 by elastolytic cathepsins. J Immunol 171 (2003) 931-937
21. Islam D., Bandholtz L., Nilsson J., et al. Downregulation of bactericidal peptides in enteric infections: a novel immune escape mechanism with bacterial DNA as a potential regulator. Nat Med 7 (2000) 180-185
22. Meyer K.C., Sharma A., Brown R., et al. Function and composition of pulmonary surfactant and surfactant-derived fatty acid profiles are altered in young adults with cystic fibrosis. Chest 118 (2000) 164-174
23. Noah T.L., Murphy P.C., Alink J.J., et al. Bronchoalveolar lavage fluid surfactant protein-A and surfactant protein-D are inversely related to inflammation in early cystic fibrosis. Am J Respir Crit Care Med 168 (2003) 685-691
24. Townsend D.M., Tew K.D., and Tapiero H. The importance of glutathione in human disease. Biomed Pharmacother 57 (2003) 145-155
25. Gao L., Kim K.J., Yankaskas J.R., and Forman H.J. Abnormal glutathione transport in cystic fibrosis airway epithelia. Am J Physiol 277 1 Pt 1 (1999) L113-118
26. Kogan I., Ramjeesingh M., Li C., et al. CFTR directly mediates nucleotide-regulated glutathione flux. EMBO J 22 (2003) 1981-1989
27. Roum J.H., Buhl R., McElvaney N.G., Borok Z., and Crystal R.G. Systemic deficiency of glutathione in cystic fibrosis. J Appl Physiol 75 (1993) 2419-2424
28. Day B.J. Glutathione: a radical treatment for cystic fibrosis lung disease?. Chest 127 (2005) 12-14
29. Childers M., Eckel G., Himmel A., and Caldwell J. A new model of cystic fibrosis pathology: lack of transport of glutathione and its thiocyanate conjugates. Med Hypotheses 68 (2007) 101-112
30. Hudson V.M. Rethinking cystic fibrosis pathology: the critical role of abnormal reduced glutathione (GSH) transport caused by CFTR mutation. Free Radic Biol Med 30 (2001) 1440-1461
31. Hudson V.M. Differing compartments of intracellular glutathione have differing levels of glutathione in cystic fibrosis. Med Hypotheses 68 (2007) 919-920
32. Roum J.H., Borok Z., McElvaney N.G., et al. Glutathione aerosol suppresses lung epithelial surface inflammatory cell-derived oxidants in cystic fibrosis. J Appl Physiol 87 (1999) 438-443
33. Cantin AM, White TB, Cross CE, Forman HJ, Sokol RJ, Borowitz D. Antioxidants in cystic fibrosis. Conclusions from the CF antioxidant workshop, Bethesda, Maryland, November 11-12, 2003. Free Radic Biol Med 2007; 42: 15-31.
34. Weldon S., McGarry N., Taggart C.C., and McElvaney N.G. The role of secretory leucoprotease inhibitor in the resolution of inflammatory responses. Biochem Soc Trans 35 Pt 2 (2007) 273-276
35. Griese M., Latzin P., Kappler M., et al. Alpha1-antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients. Eur Respir J 29 (2007) 240-250
36. Gaggar A., Li Y., Weathington N., et al. Matrix metalloprotease-9 dysregulation in lower airway secretions of cystic fibrosis patients. Am J Physiol Lung Cell Mol Physiol 293 (2007) L96-104
37. Cantin A.M., Lafrenaye S., and Begin R.O. Antineutrophil elastase activity in cystic fibrosis serum. Pediatr Pulmonol 11 (1991) 249-253
38. Martin S.L., Downey D., Bilton D., Keogan M.T., Edgar J., and Elborn J.S. Safety and efficacy of recombinant alpha(1)-antitrypsin therapy in cystic fibrosis. Pediatr Pulmonol 41 (2006) 177-183
39. Vandivier R.W., Fadok V.A., Hoffmann P.R., et al. Elastase-mediated phosphatidylserine receptor cleavage impairs apoptotic cell clearance in cystic fibrosis and bronchiectasis. J Clin Invest 109 (2002) 661-670
40. Vandivier R.W., Fadok V.A., Ogden C.A., et al. Impaired clearance of apoptotic cells from cystic fibrosis airways. Chest 121 Suppl. 3 (2002) 89S
41. Bonfield T.L., Konstan M.W., Burfeind P., Panuska J.R., Hilliard J.B., and Berger M. Normal bronchial epithelial cells constitutively produce the anti-inflammatory cytokine interleukin-10, which is downregulated in cystic fibrosis. Am J Respir Cell Mol Biol 13 (1995) 257-261
42. Knight R.A., Kollnberger S., Madden B., Yacoub M., and Hodson M.E. Defective antigen presentation by lavage cells from terminal patients with cystic fibrosis. Clin Exp Immunol 107 (1997) 542-547
43. Di A., Brown M.E., Deriy L.V., et al. CFTR regulates phagosome acidification in macrophages and alters bactericidal activity. Nat Cell Biol 8 (2006) 933-944
44. Starner T., Barker C., Jia H., Kang Y., and McCray P.J. CCL20 is an inducible product of human airway epithelia with innate immune properties. Am J Respir Cell Mol Biol 29 (2003) 627-633
45. Lambrecht B. Alveolar macrophage in the driver's seat. Immunity 24 (2006) 366-368
46. Takabayshi K., Corr M., Hayashi T., et al. Induction of a homeostatic circuit in lung tissue by microbial compounds. Immunity 24 (2006) 475-487
47. Armstrong D.S., Hook S.M., Jamsen K.M., et al. Lower airway inflammation in infants with cystic fibrosis detected by newborn screening. Pediatr Pulmonol 40 (2005) 500-510
48. Rosenfeld M., Gibson R.L., McNamara S., et al. Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis. Pediatr Pulmonol 32 (2001) 356-366
49. Muhlebach M.S., and Noah T.L. Endotoxin activity and inflammatory markers in the airways of young patients with cystic fibrosis [comment]. Am J Respir Crit Care Med 165 (2002) 911-915
50. Alexis N.E., Muhlebach M.S., Peden D.B., and Noah T.L. Attenuation of host defense function of lung phagocytes in young cystic fibrosis patients. J Cyst Fibros 5 (2006) 17-25
51. Griese M., Essl R., Schmidt R., et al. Pulmonary surfactant, lung function, and endobronchial inflammation in cystic fibrosis. Am J Respir Crit Care Med 170 (2004) 1000-1005
52. Graff I., Schram-Doumont A., and Szpirer C. Defective protein kinase C-mediated actions in cystic fibrosis neutrophils. Cell Signal 3 (1991) 259-266
53. Koller D.Y., Urbanek R., and Gotz M. Increased degranulation of eosinophil and neutrophil granulocytes in cystic fibrosis. Am J Respir Crit Care Med 152 (1995) 629-633
54. Brockbank S., Downey D., Elborn J.S., and Ennis M. Effect of cystic fibrosis exacerbations on neutrophil function. Int Immunopharmacol 5 (2005) 601-608
55. Ratjen F., Hartog C.M., Paul K., Wermelt J., and Braun J. Matrix metalloproteases in BAL fluid of patients with cystic fibrosis and their modulation by treatment with dornase alpha. Thorax 57 (2002) 930-934
56. Sagel S.D., Kapsner R.K., and Osberg I. Induced sputum matrix metalloproteinase-9 correlates with lung function and airway inflammation in children with cystic fibrosis. Pediatr Pulmonol 39 (2005) 224-232
57. Watt A.P., Courtney J., Moore J., Ennis M., and Elborn J.S. Neutrophil cell death, activation and bacterial infection in cystic fibrosis. Thorax 60 (2005) 659-664
58. Brennan S., Cooper D., and Sly P.D. Directed neutrophil migration to IL-8 is increased in cystic fibrosis: a study of the effect of erythromycin. Thorax 56 (2001) 62-64
59. Painter R.G., Valentine V.G., Lanson Jr. N.A., et al. CFTR Expression in human neutrophils and the phagolysosomal chlorination defect in cystic fibrosis. Biochemistry 5 (2006) 10260-10269
60. Moraes T.J., Plumb J., Martin R., et al. Abnormalities in the pulmonary innate immune system in cystic fibrosis. Am J Respir Cell Mol Biol 34 (2006) 364-374
61. Corvol H., Fitting C., Chadelat K., et al. Distinct cytokine production by lung and blood neutrophils from children with cystic fibrosis. Am J Physiol Lung Cell Mol Physiol 284 (2003) L997-L1003
62. Moskwa P., Lorentzen D., Excoffon K.J., et al. A novel host defense system of airways is defective in cystic fibrosis. Am J Respir Crit Care Med 175 (2007) 174-183
63. Zhang Z., Louboutin J.P., Weiner D.J., Goldberg J.B., and Wilson J.M. Human airway epithelial cells sense Pseudomonas aeruginosa infection via recognition of flagellin by Toll-like receptor 5. Infect Immun 73 (2005) 7151-7160
64. Machen T.E. Innate immune response in CF airway epithelia: hyperinflammatory?. Am J Physiol Cell Physiol 291 (2006) C218-C230
65. Velsor L.W., van Heeckeren A., and Day B.J. Antioxidant imbalance in the lungs of cystic fibrosis transmembrane conductance regulator protein mutant mice. Am J Physiol Lung Cell Mol Physiol 281 (2001) L31-L38
66. Xu Y., Liu C., Clark J.C., and Whitsett J.A. Functional genomic responses to cystic fibrosis transmembrane conductance regulator (CFTR) and CFTR(delta508) in the lung. J Biol Chem 281 (2006) 11279-11291
67. Kettle A.J., Chan T., Osberg I., et al. Myeloperoxidase and protein oxidation in the airways of young children with cystic fibrosis. Am J Respir Crit Care Med 170 (2004) 1317-1323
68. Tabary O., Escotte S., Couetil J.P., et al. High susceptibility for cystic fibrosis human airway gland cells to produce IL-8 through the I kappa B kinase alpha pathway in response to extracellular NaCl content. J Immunol 164 (2000) 3377-3384
69. Hayashi F., Means T.K., and Luster A.D. Toll-like receptors stimulate human neutrophil function. Blood 102 (2003) 2660-2669
70. Martin A.C., Laing I.A., Zhang G., et al. CD14 C-159T and early infection with Pseudomonas aeruginosa in children with cystic fibrosis. Respir Res 6 (2005) 63
71. Plant B.J., Gallagher C.G., Bucala R., et al. Cystic fibrosis, disease severity, and a macrophage migration inhibitory factor polymorphism. Am J Respir Crit Care Med 172 (2005) 1412-1415
72. Hauber H.P., Tulic M.K., Tsicopoulos A., et al. Toll-like receptors 4 and 2 expression in the bronchial mucosa of patients with cystic fibrosis. Can Respir J 12 (2005) 13-18
73. Muir A., Soong G., Sokol S., et al. Toll-like receptors in normal and cystic fibrosis airway epithelial cells. Am J Respir Cell Mol Biol 30 (2004) 777-783
74. Urquhart D.S., Allen J., Elrayess M., Fidler K., Klein N., and Jaffe A. Modifier effect of the Toll-like receptor 4 D299G polymorphism in children with cystic fibrosis. Arch Immunol Ther Exp (Warsz) 54 (2006) 271-276
75. Rubio F., Cooley J., Accurso F.J., and Remold-O'Donnell E. Linkage of neutrophil serine proteases and decreased surfactant protein-A (SP-A) levels in inflammatory lung disease. Thorax 59 (2004) 318-323
76. Day B.J., van Heeckeren A.M., Min E., and Velsor L.W. Role for cystic fibrosis transmembrane conductance regulator protein in a glutathione response to bronchopulmonary pseudomonas infection. Infect Immun 72 (2004) 2045-2051
77. Starosta V., Rietschel E., Paul K., Baumann U., and Griese M. Oxidative changes of bronchoalveolar proteins in cystic fibrosis. Chest 129 (2006) 431-437
78. Tirouvanziam R., Conrad C.K., Bottiglieri T., Herzenberg L.A., Moss R.B., and Herzenberg L.A. High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis. Proc Natl Acad Sci U S A 103 (2006) 4628-4633
79. Griese M., Ramakers J., Krasselt A., et al. Improvement of alveolar glutathione and lung function but not oxidative state in cystic fibrosis. Am J Respir Crit Care Med 169 (2004) 822-828
80. Bishop C., Hudson V.M., Hilton S.C., and Wilde C. A pilot study of the effect of inhaled buffered reduced glutathione on the clinical status of patients with cystic fibrosis. Chest 127 (2005) 308-317
81. Renner S., Rath R., Rust P., et al. Effects of beta-carotene supplementation for six months on clinical and laboratory parameters in patients with cystic fibrosis. Thorax 56 (2001) 48-52
82. Wood L.G., Fitzgerald D.A., Lee A.K., and Garg M.L. Improved antioxidant and fatty acid status of patients with cystic fibrosis after antioxidant supplementation is linked to improved lung function. Am J Clin Nutr 77 (2003) 150-159
83. Chmiel J.F., and Konstan M.W. Inflammation and anti-inflammatory therapies for cystic fibrosis. Clin Chest Med 28 (2007) 331-346
84. De Rose V., Arduino C., Cappello N., et al. Fcgamma receptor IIA genotype and susceptibility to P. aeruginosa infection in patients with cystic fibrosis. Eur J Hum Genet 13 (2005) 96-101
85. Vanscoy L.L., Blackman S.M., Collaco J.M., et al. Heritability of lung disease severity in cystic fibrosis. Am J Respir Crit Care Med 175 (2007) 1036-1043
86. Olesen H.V., Jensenius J.C., Steffensen R., Thiel S., and Schiotz P.O. The mannan-binding lectin pathway and lung disease in cystic fibrosis - disfunction of mannan-binding lectin-associated serine protease 2 (MASP-2) may be a major modifier. Clin Immunol 121 (2006) 324-331
87. Knowles M.R. Gene modifiers of lung disease. Curr Opin Pulm Med 12 (2006) 416-421
88. Ferrante A., Martin A.J., Bates E.J., et al. Killing of Staphylococcus aureus by tumor necrosis factor-alpha-activated neutrophils. The role of serum opsonins, integrin receptors, respiratory burst, and degranulation. J Immunol 151 (1993) 4821-4828
89. 2+-dependent mitogen-activated protein kinase signaling pathways in airway epithelial cells. J Biol Chem 276 (2001) 19267-19275
90. Downey D.G., Martin S.L., Dempster M., et al. The relationship of clinical and inflammatory markers to outcome in stable patients with cystic fibrosis. Pediatr Pulmonol 42 (2007) 216-220
91. Fink J., Steer J.H., Joyce D.A., McWilliam A.S., and Stewart G.A. Pro-inflammatory effects of Burkholderia cepacia on cystic fibrosis respiratory epithelium. FEMS Immunol Med Microbiol 38 (2003) 273-282
92. Usher L.R., Lawson R.A., Geary I., et al. Induction of neutrophil apoptosis by the Pseudomonas aeruginosa exotoxin pyocyanin: a potential mechanism of persistent infection. J Immunol 168 (2002) 1861-1868
93. Jesaitis A.J., Franklin M.J., Berglund D., et al. Compromised host defense on Pseudomonas aeruginosa biofilms: characterization of neutrophil and biofilm interactions. J Immunol 171 (2003) 4329-4339
94. Dockrell D.H., and Whyte M.K. Regulation of phagocyte lifespan in the lung during bacterial infection. J Leukoc Biol 79 (2006) 904-908
95. Sedor J., Hogue L., Akers K., Boslaugh S., Schreiber J., and Ferkol T. Cathepsin-G interferes with clearance of Pseudomonas aeruginosa from mouse lungs. Pediatr Res 61 (2007) 26-31
96. Hoiby N., Krogh Johansen H., Moser C., Song Z., Ciofu O., and Kharazmi A. Pseudomonas aeruginosa and the in vitro and in vivo biofilm mode of growth. Microbes Infect 3 (2001) 23-35
97. Worlitzsch D., Tarran R., Ulrich M., et al. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest 109 (2002) 317-325
98. Ciofu O., Riis B., Pressler T., Poulsen H.E., and Hoiby N. Occurrence of hypermutable Pseudomonas aeruginosa in cystic fibrosis patients is associated with the oxidative stress caused by chronic lung inflammation. Antimicrob Agents Chemother 49 (2005) 2276-2282
99. Walker T.S., Tomlin K.L., Worthen G.S., et al. Enhanced Pseudomonas aeruginosa biofilm development mediated by human neutrophils. Infect Immun 73 (2005) 3693-3701
100. Delgado M.A., Poschet J.F., and Deretic V. Nonclassical pathway of Pseudomonas aeruginosa DNA-induced interleukin-8 secretion in cystic fibrosis airway epithelial cells. Infect Immun 74 (2006) 2975-2984